JP2022096991A - 外用医薬組成物 - Google Patents
外用医薬組成物 Download PDFInfo
- Publication number
- JP2022096991A JP2022096991A JP2020210317A JP2020210317A JP2022096991A JP 2022096991 A JP2022096991 A JP 2022096991A JP 2020210317 A JP2020210317 A JP 2020210317A JP 2020210317 A JP2020210317 A JP 2020210317A JP 2022096991 A JP2022096991 A JP 2022096991A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- external pharmaceutical
- isopropyl myristate
- salt
- loxoprofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 56
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229960002373 loxoprofen Drugs 0.000 claims abstract description 30
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims abstract 3
- 239000006185 dispersion Substances 0.000 abstract description 15
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- -1 alkali metal salts Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020210317A JP2022096991A (ja) | 2020-12-18 | 2020-12-18 | 外用医薬組成物 |
| TW110142463A TW202228668A (zh) | 2020-12-18 | 2021-11-16 | 外用醫藥組成物 |
| PCT/JP2021/044977 WO2022131082A1 (fr) | 2020-12-18 | 2021-12-07 | Composition pharmaceutique à usage externe |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020210317A JP2022096991A (ja) | 2020-12-18 | 2020-12-18 | 外用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022096991A true JP2022096991A (ja) | 2022-06-30 |
Family
ID=82057740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020210317A Pending JP2022096991A (ja) | 2020-12-18 | 2020-12-18 | 外用医薬組成物 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2022096991A (fr) |
| TW (1) | TW202228668A (fr) |
| WO (1) | WO2022131082A1 (fr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10120560A (ja) * | 1996-08-26 | 1998-05-12 | Sankyo Co Ltd | ロキソプロフェン含有外用製剤 |
| EP2116234A4 (fr) * | 2006-12-06 | 2012-01-18 | Nipro Patch Co Ltd | Composition pharmaceutique pour application externe et timbre dermique adhesif |
| CA2857156C (fr) * | 2011-12-01 | 2019-09-24 | Teikoku Seiyaku Co., Ltd. | Timbre adhesif contenant du ropinirole |
| JP6516083B2 (ja) * | 2013-06-05 | 2019-05-22 | 国立大学法人九州大学 | 経皮吸収基材 |
| CN110198715A (zh) * | 2017-02-03 | 2019-09-03 | 考司美德制药株式会社 | 含有罗替戈汀的透皮吸收型贴剂 |
| JP7186025B2 (ja) * | 2018-06-27 | 2022-12-08 | 小林製薬株式会社 | 外用医薬組成物 |
| JP7164976B2 (ja) * | 2018-06-27 | 2022-11-02 | 小林製薬株式会社 | 外用医薬組成物 |
| JP7186024B2 (ja) * | 2018-06-27 | 2022-12-08 | 小林製薬株式会社 | 外用医薬組成物 |
-
2020
- 2020-12-18 JP JP2020210317A patent/JP2022096991A/ja active Pending
-
2021
- 2021-11-16 TW TW110142463A patent/TW202228668A/zh unknown
- 2021-12-07 WO PCT/JP2021/044977 patent/WO2022131082A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022131082A1 (fr) | 2022-06-23 |
| TW202228668A (zh) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL177592B1 (pl) | Kompozycja farmaceutyczna lub weterynaryjna w postaci kremu | |
| JPS5815909A (ja) | 抗真菌外用剤 | |
| JP3802105B2 (ja) | ジクロフェナクナトリウム含有乳化外用剤 | |
| KR0168436B1 (ko) | 비스테로이드계 소염진통제를 함유하는 수중유형 유화 조성물 | |
| JPS63255216A (ja) | 坐剤基剤乳化組成物およびそれを含有する坐剤 | |
| JPH07188027A (ja) | 安定な酪酸ヒドロコルチゾン含有クリーム剤 | |
| WO2022131082A1 (fr) | Composition pharmaceutique à usage externe | |
| JP2022096997A (ja) | 外用医薬組成物 | |
| US5100908A (en) | Antimycotic external imidazole preparations | |
| JP2022096992A (ja) | 外用医薬組成物 | |
| JP2022096993A (ja) | 外用医薬組成物 | |
| JPS5987035A (ja) | 尿素を安定に含むｗ／ｏ型エマルジヨン組成物 | |
| JPH0129170B2 (fr) | ||
| WO2022131080A1 (fr) | Composition émulsifiée à usage externe | |
| JPH0461847B2 (fr) | ||
| JP2007001965A (ja) | 乳化組成物およびそれを含有した化粧料 | |
| JP5011118B2 (ja) | インドメタシンを含有する外用液剤 | |
| WO2022131081A1 (fr) | Composition émulsifiée pour application externe | |
| JP4774691B2 (ja) | ジメチルイソプロピルアズレン含有外用剤 | |
| JPH06264049A (ja) | 化粧料または皮膚外用剤の稠度改善剤 | |
| JP7226957B2 (ja) | 外用医薬組成物 | |
| JP2022178154A (ja) | 外用組成物 | |
| JP2023090338A (ja) | 乳化組成物 | |
| JP2022178158A (ja) | 外用組成物 | |
| JPS63146817A (ja) | 外用抗真菌剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231129 |